Skip to main content

Ovarian Cancer

Phase 3 SOLO1 Subgroup Analysis Based on Olaparib-Treated, Low- and High-Risk Patients with Ovarian Cancer and BRCA Mutation

Risk of Secondary Hematologic Malignancy Not Significantly Increased by PARP Inhibitors

NOVA Clinical Trial versus Real-World Data: Niraparib Treatment Outcomes in Patients with BRCA–Wild-Type, Platinum-Sensitive, Recurrent Ovarian Cancer

In Women with Relapsed Ovarian Cancer and BRCA Mutation, Olaparib Extends Survival by >1 Year

Patients with Newly Diagnosed Stage III or IV Ovarian Cancer and Atezolizumab

Subsequent Chemotherapy Following Olaparib Maintenance Therapy in BRCA1/2 Mutated Platinum-Sensitive Recurrent Epithelial Ovarian Cancer

Treatment Strategies and Survival in Women with Malignant Ovarian Germ Cell Tumors

Deleterious BRCA Mutations More Likely on Long-Term Responders to Rucaparib

In Patients with Ovarian Cancer and Non-BRCA HRR Gene Mutations, Promising Results Seen with Maintenance Rucaparib

Maintenance Therapy with Olaparib plus Bevacizumab in Newly Diagnosed Advanced High‐Grade Ovarian Carcinoma

2
3
4
5
6
7
8

Page 5 of 13
Results 41 - 50 of 125